A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca will record sales in other countries worldwide, for which profits shared with Daiichi Sankyo will be recorded within cost of sales. Daiichi Sankyo will manufacture and supply DS-1062.

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.

TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Additionally, Daiichi Sankyo and its Enhertu commercial partner AstraZeneca demonstrated excellent commercial decision-making by pursuing approval for the newly defined HER2-Low breast cancer ...

The campaign is presented by Daiichi-Sankyo and AstraZeneca, while Merck serves as a gold-level sponsor and Eli Lilly, Pfizer and Guardant come aboard as community sponsors. In the campaign’s ...

Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of ...

and being jointly developed by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). TROPION-Lung10 is evaluating datopotamab deruxtecan plus rilvegostomig, AstraZeneca’s PD-1/TIGIT bispecific ...